|
Volumn 86, Issue 5, 2002, Pages 669-673
|
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer
a a a a a a a a a |
Author keywords
Advanced oesophageal cancer; Chemotherapy; Cisplatin; Paclitaxel
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CISPLATIN;
PACLITAXEL;
ADULT;
AGED;
ARTICLE;
BONE MARROW TOXICITY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
ESOPHAGUS CANCER;
FEMALE;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
NEUROTOXICITY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
ADENOCARCINOMA;
ADULT;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, SQUAMOUS CELL;
CISPLATIN;
DISEASE PROGRESSION;
DRUG ADMINISTRATION SCHEDULE;
ESOPHAGEAL NEOPLASMS;
ESOPHAGOGASTRIC JUNCTION;
FEMALE;
HUMANS;
INFUSIONS, INTRAVENOUS;
MALE;
MIDDLE AGED;
NERVOUS SYSTEM;
NEUTROPENIA;
PACLITAXEL;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
EID: 0037017838
PISSN: 00070920
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.bjc.6600166 Document Type: Article |
Times cited : (85)
|
References (23)
|